Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
h5G1.1-mAb in Dermatomyositis
NCT00005571Phase 2Completed
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
- Start
- Apr 2000
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of eculizumab in dermatomyositis (DM), sponsored by National Institute of Arthritis and Musculoskeletal and Skin Diseases. Started Apr 2000; status: completed.
02
Drugs
eculizumab
03
Conditions
dermatomyositis (DM)
Beyond the preview
Go deeper on NCT00005571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00005571.